Market Overview

A Peek Into The Market Before The Trading Starts

Related TEVA
UPDATE: Sterne Agee Upgrades Teva Pharmaceutical
Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic Competition
Sofinnova Ventures Closes $500M Fund (Fox Business)
Related SSRX
3SBio Shareholders Approve Amended Merger Agreement
UPDATE: 3SBio Enters 'Go Private' Deal, Consideration Raised to $2.3857/Share or $16.70/ADS

Pre-open movers US stock futures are mostly flat this morning, as investors are awaiting trade data. Futures for the Dow Jones Industrial Average dropped 1 point to 13,897.00 and S&P 500 index futures rose 1.20 points to 1,506.50. Nasdaq 100 futures climbed 4.75 points to 2,746.75.

A Peek Into Global Markets European markets were mostly higher today. The STOXX Europe 600 Index rose 0.62%, London's FTSE 100 Index gained 0.54%, German DAX 30 Index rose 0.41% and French CAC 40 Index climbed 0.68%.

Asian markets ended mostly higher, with Japan's Nikkei Stock Average falling 1.80%, China's Shanghai Composite gaining 0.57% and Australia's S&P/ASX 200 Index rising 0.68%. Hong Kong's Hang Seng Index climbed 0.16% and India's Sensex fell 0.49%.

Broker Recommendation Analysts at Canaccord downgraded Teva Pharmaceutical Industries (NYSE: TEVA) from “buy” to “hold.” The target price for Teva has been raised from $50 to $45.

Teva shares dropped 0.11% to $37.92 in pre-market trading.

Breaking news

  • 3SBio (NASDAQ: SSRX) today announced that it has entered into an agreement and plan of merger with Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands, and Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent. To read the full news, click here.
  • Tranzyme (NASDAQ: TZYM) announced today that its board has made a determination to explore and evaluate strategic alternatives, including the possibility of a merger, sale, other form of business combination, or other transaction. To read the full news, click here.
  • Oncolytics Biotech (NASDAQ: ONCY) today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel. To read the full news, click here.
  • Laboratory Corp of America Holdings (NYSE: LH) reported a decline in its Q4 profit. To read the full news, click here.

Posted-In: Canaccord US Stock FuturesNews Futures Global Pre-Market Outlook Markets

 

Related Articles (ONCY + LH)

Around the Web, We're Loving...

Get Benzinga's Newsletters